Summary Stage 2018: Mycosis Fungoides

Summary Stage 2018

Notes

**Mycosis Fungoides** 9700-9701 (C000-C809) **Note 1:** The following sources were used in the development of this chapter * SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf) * SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/) * Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx * Chapter 81 *Primary Cutaneous Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. **Note 2:** Code 0 is not applicable for this chapter. **Note 3:** All lymph node (regional and distant) involvement is coded as regional lymph node involvement. **Note 4:** Visceral involvement is metastatic disease and should be questioned in the absence of node or blood involvement.

NAACCR Item

NAACCR #764
SS2018 Description
1 Localized only (localized, NOS) - MFCG Stage I + Less than 10% of skin surface, no tumors + Limited to patches, papules, or plaques - MFCG Stage II + Greater than or equal to 10% of skin surface, no tumors + Generalized patches, papules, or plaques - Not stated whether patches, papules, or plaques + % of body surface not stated, no tumors + Skin involvement, NOS: extent not stated, no tumors
2 Regional by direct extension only - MFCG Stage III + Cutaneous tumor, size not stated + Generalized erythroderma (confluence of erythemia) * (greater than 50% of body involved with diffuse redness) + One or more tumors equal to 1 cm or greater + Sezary syndrome + Skin lesion described as tumor less than 1 cm
3 Regional lymph node(s) involved only - Both clinically enlarged palpable lymph node(s) (adenopathy) AND + pathologically positive nodes - Clinically enlarged palpable lymph node(s) (adenopathy) AND + either pathologically negative nodes or no pathological statement - No clinically enlarged palpable lymph node(s) (adenopathy) BUT + pathologically positive lymph node(s) - Dutch grade 1-4 OR NCI LN 0-4 + Clone positive, negative or unknown - Regional lymph node(s), NOS + Lymph node(s), NOS
4 Regional by BOTH direct extension AND regional lymph node(s) involved - Codes (2) + (3)
7 Distant site(s) involved - Distant site(s) (including further contiguous extension) + MFCG Stage IV * Bone marrow * Involvement by at least one organ outside the skin, nodes, blood, or bone marrow * Liver * Spleen * Visceral (non-cutaneous, extranodal) involvement, pathologically confirmed - Distant metastasis, NOS + Carcinomatosis
9 Unknown if extension or metastasis
(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998 (2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001. (3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL) (4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017 (5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017 (6) Rosen, S.T., Jaffe, E.S., Leonard, J.P., et al. **Primary Cutaneous Lymphomas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017